PharmaTher Develops 3D-Printed Oral Peptides
The firm is utilizing a new federal compounding pathway to deliver KPV and BPC-157 via 3D-printing technology.
Updated on Oct. 29, 2026 in Biotech
PharmaTher Holdings Ltd. has announced the development of 3D-printed oral peptide products, including KPV and BPC-157. These products utilize patent-pending CORR3CT technology to ensure targeted release in the colon.
Why it matters
This development follows a new policy from the U.S. Department of Health and Human Services that establishes a conditional pathway for pharmacies to compound six specific peptides. The move aims to utilize 3D-printing platforms to standardize the delivery of peptides that previously faced challenges surviving the stomach environment.
The development leverages the M3DICINES 3D-printed medicines platform to integrate CORR3CT technology. This design enables the medication to bypass stomach acidity for site-specific release in the colon.
The players
PharmaTher Holdings Ltd.
A company focused on developing specialty pharmaceutical products, including 3D-printed dosage forms for peptide delivery.
U.S. Department of Health and Human Services
The federal agency responsible for establishing the regulatory framework that now permits the compounding of specific peptides.
Craft Health Pte. Ltd.
A developer of 3D-printing technologies for medicine, responsible for the CORR3CT targeted-delivery system.
The details
The technology works by fabricating dosage forms through 3D printing that protect the peptide active ingredients during transit through the upper gastrointestinal tract. CORR3CT technology acts as the structural framework that ensures the oral product remains intact until it reaches the colonic environment, where the drug is released. This approach represents a shift from traditional compounding, which often struggles with the precise delivery of peptides that are prone to degradation.
Timeline
October 29, 2026: PharmaTher Holdings announced the peptide portfolio development.
The Tech Race
The expansion into 3D-printed peptides reflects a race to modernize pharmaceutical compounding under the new U.S. Department of Health and Human Services guidelines. This effort directly competes with traditional pill manufacturing by providing a faster, automated pathway for customized, stable dose delivery.
The development intends to enable easier access to KPV and BPC-157 for patients requiring these specific peptides. Commercialization is planned for the near term, though precise availability and patient costs are still under development.
The takeaway
This development marks a shift toward leveraging 3D printing to comply with emerging U.S. compounding regulations for peptides. Patients and providers should watch for near-term commercial rollout updates from compounding pharmacies utilizing the approved HHS pathway.
Further reading
Learn more about the latest innovations in pharmaceutical manufacturing at Biotech.
Source note: This article includes information reported by The Kingston Whig-Standard.
